Loading clinical trials...
Loading clinical trials...
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Conditions
Interventions
Lenalidomide
Dexamethasone
+3 more
Locations
11
United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Investigative Clinical Research Of Indiana, Llc
Indianapolis, Indiana, United States
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, United States
University Of Maryland
Baltimore, Maryland, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Washington University School Of Medicine
St Louis, Missouri, United States
Start Date
January 6, 2012
Primary Completion Date
March 21, 2014
Completion Date
July 18, 2016
Last Updated
August 3, 2017
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions